EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pan-cancer multi-omics profiling of OAS3 reveals its immunological and prognostic associations across human cancers

Xi Zhang, Hongyan Zhang, Liang Zhong, Wei Yang, Chunhui Yang, Yuqing Pan, Beizhong Liu

PeerJ · 2026

DOI: 10.7717/peerj.20805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2026. Verfasst von Xi Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory of Yong-Chuan Hospital, Chongqing University of Medical Science, Chongqing, China. Hauptthemen laut MEDLINE: 2',5'-Oligoadenylate Synthetase, Neoplasms. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Science and Technology Bureau’s Key Technology Innovation Special of Key Industries, Yunnan Provincial Health Commission’s Reserve Talent Development Program for Medical Disciplines, Scientific Research Fund of Education Department of Yunnan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The enzyme 2′-5′-oligoadenylate synthetase 3 (OAS3) plays a well-established role in antiviral immunity, but its involvement in cancer biology remains poorly understood. This study aimed to comprehensively investigate the expression patterns, mutation characteristics, prognostic significance, functional roles, and therapeutic potential of OAS3 across multiple cancer types.

Methods

Utilizing multi-omics data from public cancer databases, we analyzed OAS3 expression patterns, survival correlations, immune interactions, pathway enrichment, genomic associations, mutation profiles, and functional validation of OAS3 knockdown in THP-1 cells for apoptosis assays.

Results

OAS3 expression was significantly upregulated in 32 cancer types, highlighting its context-dependent roles as an oncogene. The expression patterns of OAS3 were found to be stage-specific and cancer-specific across multiple tumor types. Survival analysis revealed that high OAS3 expression was significantly associated with unfavorable prognosis in several cancers. Further analyses demonstrated that OAS3 expression was correlated with immune-related genes, immune checkpoints, tumor stemness, and immune cell infiltration across multiple tumor types. Moreover, gene set enrichment profiling revealed significant involvement of OAS3 in interferon response and immune regulation, with prominent enrichment in Janus kinase-signal transducer and activator of transcription (JAK-STAT) and Notch signaling pathways. Mutation analysis highlighted high mutation frequencies of OAS3 in several cancer types, especially in endometrial cancer and melanoma. Comprehensive molecular profiling further identified significant associations between OAS3 expression levels and key genomic features (tumor mutation burden, homologous recombination deficiency and RNA modification-related proteins). Besides, OAS3’s expression was associated with key processes such as cell cycle regulation and immune evasion, further underscoring its potential as a therapeutic target in lung and breast cancers. Finally, we found that OAS3 was observably related with some mutation types (CEBPA, FLT3 internal tandem duplication, NRAS, and EVI1 expression) in patients with acute myeloid leukemia (LAML). Functional validation through RNA interference demonstrated that OAS3 knockdown significantly induced apoptosis in THP-1 cells.

Conclusion

This study demonstrates that OAS3 acts as a pivotal modulator in the complex network of cancer progression, highlighting its dual role in both tumorigenesis and immune response regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

2',5'-Oligoadenylate SynthetaseNeoplasmsHumansPrognosisGene Expression Regulation, NeoplasticMultiomicsMutationGene Expression ProfilingApoptosisBiomarkers, Tumor

Stichwörter der Autor:innen

Pan-cancerImmune infiltrationImmune modulationOAS3Prognostic biomarker

Substanzen

2',5'-Oligoadenylate SynthetaseOAS3 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Central Laboratory of Yong-Chuan Hospital, Chongqing University of Medical Science, Chongqing, China.
  • Key Laboratory of Laboratory Medical Diagnostics, Chongqing University of Medical Science, Chongqing, China.
  • Department of Clinical Laboratory, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, China.
  • Yunnan Key Laboratory of Laboratory Medicine, Kunming Medical University, Kunming, China.
  • Clinical Laboratory of the Affiliated Rehabilitation Hospital, Chongqing University of Medical Science, Chongqing, China.

Förderung

  • Chongqing Science and Technology Bureau’s Key Technology Innovation Special of Key Industries
  • Yunnan Provincial Health Commission’s Reserve Talent Development Program for Medical Disciplines
  • Scientific Research Fund of Education Department of Yunnan Province

Zitieren

APA

Zhang, X., Zhang, H., Zhong, L., Yang, W., Yang, C., Pan, Y., & Liu, B. (2026). Pan-cancer multi-omics profiling of OAS3 reveals its immunological and prognostic associations across human cancers. PeerJ. https://doi.org/10.7717/peerj.20805

Vancouver

Zhang X, Zhang H, Zhong L, Yang W, Yang C, Pan Y, et al. Pan-cancer multi-omics profiling of OAS3 reveals its immunological and prognostic associations across human cancers. PeerJ. 2026. doi:10.7717/peerj.20805

BibTeX
@article{Zhang2026,
  author = {Zhang, Xi and Zhang, Hongyan and Zhong, Liang and Yang, Wei and Yang, Chunhui and Pan, Yuqing and Liu, Beizhong},
  title = {Pan-cancer multi-omics profiling of OAS3 reveals its immunological and prognostic associations across human cancers},
  journal = {PeerJ},
  year = {2026},
  doi = {10.7717/peerj.20805}
}
Kostenlos starten →